|
Name |
Antibiotic 1233A
|
Molecular Formula | C18H28O5 | |
IUPAC Name* |
(2E,4E,7R)-11-[(2R,3R)-3-(hydroxymethyl)-4-oxooxetan-2-yl]-3,5,7-trimethylundeca-2,4-dienoic acid
|
|
SMILES |
C[C@H](CCCC[C@@H]1[C@H](C(=O)O1)CO)C/C(=C/C(=C/C(=O)O)/C)/C
|
|
InChI |
InChI=1S/C18H28O5/c1-12(8-13(2)9-14(3)10-17(20)21)6-4-5-7-16-15(11-19)18(22)23-16/h9-10,12,15-16,19H,4-8,11H2,1-3H3,(H,20,21)/b13-9+,14-10+/t12-,15-,16-/m1/s1
|
|
InChIKey |
ODCZJZWSXPVLAW-KXCGKLMDSA-N
|
|
Synonyms |
Hymeglusin; Antibiotic 1233A; 29066-42-0; L-659,699; (R,R)-Hymeglusin; L 659699; (2E,4E,7R)-11-[(2R,3R)-3-(hydroxymethyl)-4-oxooxetan-2-yl]-3,5,7-trimethylundeca-2,4-dienoic acid; 1233A; Antibiotic F 244; 2,4-Undecadienoic acid, 11-[(2R,3R)-3-(hydroxymethyl)-4-oxo-2-oxetanyl]-3,5,7-trimethyl-, (2E,4E,7R)-; F 244; SCHEMBL613745; CHEMBL470269; GTPL5886; CHEBI:191049; DTXSID901318499; ZINC6036362; HB3701; 2,4-Undecadienoic acid, 11-(3-(hydroxymethyl)-4-oxo-2-oxetanyl)-3,5,7-trimethyl-, (2R-(2-alpha(2E,4E,7R*),3-beta))-; HY-117430; CS-0065979; J-017379; L659,699; (+)-F-244; L 659,699; Q27078398; 11-[3R-(hydroxymethyl)-4-oxo-2R-oxetanyl]-3,5,7R-trimethyl-2E,4E-undecadienoic acid
|
|
CAS | 29066-42-0 | |
PubChem CID | 6440895 | |
ChEMBL ID | CHEMBL470269 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 324.4 | ALogp: | 4.6 |
HBD: | 2 | HBA: | 5 |
Rotatable Bonds: | 10 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 83.8 | Aromatic Rings: | 1 |
Heavy Atoms: | 23 | QED Weighted: | 0.276 |
Caco-2 Permeability: | -4.928 | MDCK Permeability: | 0.00001750 |
Pgp-inhibitor: | 0.011 | Pgp-substrate: | 0.032 |
Human Intestinal Absorption (HIA): | 0.133 | 20% Bioavailability (F20%): | 0.123 |
30% Bioavailability (F30%): | 0.044 |
Blood-Brain-Barrier Penetration (BBB): | 0.699 | Plasma Protein Binding (PPB): | 85.68% |
Volume Distribution (VD): | 0.601 | Fu: | 16.14% |
CYP1A2-inhibitor: | 0.102 | CYP1A2-substrate: | 0.174 |
CYP2C19-inhibitor: | 0.087 | CYP2C19-substrate: | 0.281 |
CYP2C9-inhibitor: | 0.529 | CYP2C9-substrate: | 0.831 |
CYP2D6-inhibitor: | 0.043 | CYP2D6-substrate: | 0.187 |
CYP3A4-inhibitor: | 0.023 | CYP3A4-substrate: | 0.181 |
Clearance (CL): | 1.324 | Half-life (T1/2): | 0.87 |
hERG Blockers: | 0.014 | Human Hepatotoxicity (H-HT): | 0.842 |
Drug-inuced Liver Injury (DILI): | 0.733 | AMES Toxicity: | 0.029 |
Rat Oral Acute Toxicity: | 0.055 | Maximum Recommended Daily Dose: | 0.141 |
Skin Sensitization: | 0.962 | Carcinogencity: | 0.438 |
Eye Corrosion: | 0.024 | Eye Irritation: | 0.329 |
Respiratory Toxicity: | 0.081 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC006085 | 0.714 | D0N3NO | 0.308 | ||||
ENC005670 | 0.525 | D0I4DQ | 0.272 | ||||
ENC005669 | 0.478 | D0ZI4H | 0.270 | ||||
ENC004083 | 0.357 | D0T9TJ | 0.260 | ||||
ENC004082 | 0.325 | D06FEA | 0.248 | ||||
ENC003737 | 0.322 | D09ANG | 0.236 | ||||
ENC002128 | 0.315 | D03JSJ | 0.234 | ||||
ENC005668 | 0.314 | D0V0IX | 0.234 | ||||
ENC005667 | 0.314 | D00CTS | 0.214 | ||||
ENC005665 | 0.308 | D0D9NY | 0.214 |